New Anti-Tumor Agents from Pyrimido[4,5-d]pyrimidine Compounds
Author Information
Author(s): El-Moghazy Samir M., Ibrahim Diaa A., Abdelgawad Nagwa M., Farag Nahla A. H., El-Khouly Ahmad S.
Primary Institution: Cairo University
Hypothesis
Can novel pyrimido[4,5-d]pyrimidine derivatives act as effective CDK2 inhibitors and anti-tumor agents?
Conclusion
The synthesized pyrimido[4,5-d]pyrimidine derivatives demonstrated potent CDK2 inhibitory activities and inhibited tumor cell proliferation.
Supporting Evidence
- The compounds showed IC50 values less than 1 μM for CDK2, indicating strong inhibitory activity.
- Compound 7f was found to be more active than the reference compound roscovitine.
- Most compounds demonstrated selective inhibition of CDK2 over CDK4 and EGFR.
Takeaway
Scientists created new medicines from a special chemical structure that can help stop cancer cells from growing.
Methodology
The study involved designing, synthesizing, and testing new compounds for their ability to inhibit CDK2 and their effects on human tumor cells.
Limitations
Some compounds showed high theoretical activity but had moderate to low biological results, possibly due to issues with cell permeability.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website